Skip to main content Accessibility help
×
Home

The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis

  • Maarten Bak (a1) (a2), Irene Weltens (a1) (a2), Chris Bervoets (a3), Jürgen De Fruyt (a4), Jerzy Samochowiec (a5), Andrea Fiorillo (a6), Gaia Sampogna (a7), Przemyslaw Bienkowski (a8), W. Ulrich Preuss (a9), Blazej Misiak (a10), Dorota Frydecka (a11), Agnieszka Samochowiec (a12), Emma Bak (a13), Marjan Drukker (a1) and Geert Dom (a14)...

Abstract

Introduction:

Non-pharmacological interventions preferably precede pharmacological interventions in acute agitation. Reviews of pharmacological interventions remain descriptive or compare only one compound with several other compounds. The goal of this study is to compute a systematic review and meta-analysis of the effect on restoring calmness after a pharmacological intervention, so a more precise recommendation is possible.

Method:

A search in Pubmed and Embase was done to isolate RCT’s considering pharmacological interventions in acute agitation. The outcome is reaching calmness within maximum of 2 h, assessed by the psychometric scales of PANSS-EC, CGI or ACES. Also the percentages of adverse effects was assessed.

Results:

Fifty-three papers were included for a systematic review and meta-analysis. Most frequent studied drug is olanzapine. Changes on PANNS-EC and ACES at 2 h showed the strongest changes for haloperidol plus promethazine, risperidon, olanzapine, droperidol and aripiprazole. However, incomplete data showed that the effect of risperidon is overestimated. Adverse effects are most prominent for haloperidol and haloperidol plus lorazepam.

Conclusion:

Olanzapine, haloperidol plus promethazine or droperidol are most effective and safe for use as rapid tranquilisation. Midazolam sedates most quickly. But due to increased saturation problems, midazolam is restricted to use within an emergency department of a general hospital.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis
      Available formats
      ×

Copyright

Corresponding author

*Abbreviations: AB, agitated behaviour. Corresponding author at: Department of Psychiatry and Neuropsychology, Maastricht University and FACT, Mondriaan, Maastricht, p/a. PO Box 616, 6200MD, the Netherlands. E-mail address: m.bak@maastrichtuniversity.nl

References

Hide All
[1]Allen, MHCurrier, GWUse of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004;26(1):42–9.
[2]Allen, MHCurrier, GWCarpenter, DRoss, RWDocherty, JPExpert consensus panel for behavioral E. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 11(Suppl 1)2005; 5108 quiz 10-2.
[3]Allison, LMoncrieff, J‘Rapid tranquillisation’: an historical perspective on its emergence in the context of the development of antipsychotic medications. Hist Psychiatry 2014;25(1):5769.
[4]Canas, FManagement of agitation in the acute psychotic patient--efficacy without excessive sedation. Eur Neuropsychopharmacol 17(Suppl 2)2007; S10814.
[5]Garriga, MPacchiarotti, IKasper, SZeller, SLAllen, MHVazquez, G et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry 2016;17(2):86128.
[6]Belgamwar, RBFenton, MOlanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev (2)2005 CD003729.
[7]Huf, GAlexander, JGandhi, PAllen, MHHaloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2016; 11: CD005146.
[8]Khokhar, MARathbone, JDroperidol for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 2016; 12: CD002830.
[9]Ostinelli, EGBrooke-Powney, MJLi, XAdams, CEHaloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2017; 7: CD009377.
[10]Kishi, TMatsunaga, SIwata, NIntramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res 2015; 68:198209.
[11]Bervoets, CRoelant, EDe Fruyt, JDemunter, HDekeyser, BVandenbussche, L et al. Prescribing preferences in rapid tranquillisation: a survey in Belgian psychiatrists and emergency physicians. BMC Res Notes 2015; 8:218.
[13]Kay, SRFiszbein, AOpler, LAThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261–76.
[14]Baldaca, LSanches, MCordeiro, DCJackowski, APRapid tranquilisation for agitated patients in emergency psychiatric rooms: randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileira de Psiquiatria 2011;33(3):30–9.
[15]Leucht, SKane, JMKissling, WHamann, JEtschel, EEngel, RRWhat does the PANSS mean?. Schizophr Res 79(2-3)2005; 231–8.
[16]Montoya, AValladares, ALizan, LSan, LEscobar, RPaz, SValidation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 2011; 9:18.
[17]Battaglia, JLindborg, SRAlaka, KMeehan, KWright, PCalming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21(3):192–8.
[18]Meehan, KMWang, HDavid, SRNisivoccia, JRJones, BBeasley, CM Jr et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26(4):494504.
[19]Rosen, JBurgio, LKollar, MCain, MAllison, MFogleman, M et al. The Pittsburgh agitation scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry 1994;2(1):52–9.
[20]Yudofsky, SCKopecky, HJKunik, MSilver, JMEndicott, JThe Overt Agitation Severity Scale for the objective rating of agitation. J Neuropsychiatry Clin Neurosci 1997;9(4):541–8.
[21]Stroup, DFBerlin, JAMorton, SCOlkin, IWilliamson, GDRennie, D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA J Am Med Assoc 2000;283(15):2008–12.
[22]Statacorp, Statistical software: release 12. College station 2012, Stata Corporation TX.
[23]Bradburn, MJDeeks, JJAltman, JJMetan – a command for meta-analysis in stata SJAC, editors, Meta-analysis in stata: an updated collection from the stata journal 2009, Stata Press Publications College Station, Texas.
[24]De Filippis, SCuomo, ILionetto, LJaniri, DSimmaco, MCaloro, M et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy 2013;33(6):603–14.
[25]Hatta, KKawabata, TYoshida, KHamakawa, HWakajima, TFuruta, K et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 2008; 30:367–71.
[26]Lim, HKKim, JJPae, CULee, CULee, CPaik, IHComparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology 2010;62(2):81–6.
[27]Walther, SMoggi, FHorn, HMoskvitin, KAbderhalden, CMaier, N et al. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol 2014;34(1):124–8.
[28]Alexander, JTharyan, PAdams, CJohn, TMol, CPhilip, JRapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. Haloperidol plus promethazine. Br J Psychiatry 2004; 185:63–9.
[29]Calver, LDrinkwater, VIsbister, GKA prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit. BMC Psychiatry 2013; 13:225.
[30]Meehan, KZhang, FDavid, STohen, MJanicak, PSmall, J et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21(4):389–97.
[31]Richards, JRDerlet, RWDuncan, DRChemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998;16(4):567–73.
[32]Zimbroff, DLMarcus, RNManos, GStock, EMcQuade, RDAuby, P et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27(2):171–6.
[33]Huf, GoboTC, groupRapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. Br Med J 2003; 327:708–13.
[34]Isbister, GKCalver, LAPage, CBStokes, BBryant, JLDownes, MARandomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010;56(4):392401 e1.
[35]Knott, VJScherling, CSBlais, CMCamarda, JFisher, DJMillar, A et al. Acute nicotine fails to alter event-related potential or behavioral performance indices of auditory distraction in cigarette smokers. Nicotine Tob Res 2006;8(2):263–73.
[36]Andrezina, RMarcus, RNOren, DAManos, GStock, ECarson, WH et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006;22(11):2209–19.
[37]Andrezina, RJosiassen, RCMarcus, RNOren, DAManos, GStock, E et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188(3):281–92.
[38]Asadollahi, SHeidari, KHatamabadi, HVafaee, RYunesian, SAzadbakht, A et al. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol 2015;30(3):142–50.
[39]Breier, AMeehan, KBirkett, MDavid, SFerchland, ISutton, V et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59(5):441–8.
[40]Calver, LDrinkwater, VGupta, RPage, CBIsbister, GKDroperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. Br J Psychiatry 2015;206(3):223–8.
[41]Chan, HYRee, SCSu, LWChen, JJChou, SYChen, CK et al. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. J Clin Psychopharmacol 2014;34(3):355–8.
[42]Fang, MChen, HLi, LHWu, RLi, YLiu, L et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharmacol 2012;27(2):107–13.
[43]Huf, GCoutinho, ESAdams, CEGroup, TCRapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 2007;335(7625):869.
[44]Suzuki, HGen, KTakahashi, YA naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol 2014;29(1):83–8.
[45]Tran-Johnson, TKSack, DAMarcus, RNAuby, PMcQuade, RDOren, DAEfficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68(1):111–9.
[46]Wright, PBirkett, MDavid, SRMeehan, KFerchland, IAlaka, KJ et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158(7):1149–51.
[47]Mantovani, CLabate, CMSponholz, A Jrde Azevedo Marques, JMGuapo, VG de Simone Brito dos Santos M.E. et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol 2013;33(3):306–12.
[48]Raveendran, NSTharyan, PAlexander, JAdams, CETR-IIC, GroupRapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 2007;335(7625):865.
[49]Currier, GWSimpson, GMRisperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62(3):153–7.
[50]Currier, GWChou, JCFeifel, DBossie, CATurkoz, IMahmoud, RA et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65(3):386–94.
[51]Huang, CLHwang, TJChen, YHHuang, GHHsieh, MHChen, HH et al. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trial. J Formos Med Assoc 2015;114(5):438–45.
[52]Yildiz, ATurgay, AAlpay, MSachs, GSObservational data on the antiagitation effect of risperidone tablets in emrgency settings: a preliminary report. Int J Psychiatry Clin Pract 2003; 7:217–21.
[53]Hick, JLMahoney, BDLappe, MPrehospital sedation with intramuscular droperidol: a one-year pilot. Prehosp Emerg Care 2001;5(4):391–4.
[54]Taylor, DMYap, CYLKnott, JCTaylor, SEPhillips, GAKarro, J et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. Ann Emerg Med 2017;69(3):318–26 e1.
[55]Currier, GWCitrome, LLZimbroff, DLOren, DManos, GMcQuade, R et al. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract 2007;13(3):159–69.
[56]Kittipeerachon, MChaichan, WIntramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial. Schizophrenoa Research 2016; 176:231–8.
[57]Rappaport, SAMarcus, RNManos, GMcQuade, RDOren, DAA randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J Am Med Dir Assoc 2009;10(1):21–7.
[58]Centorrino, FMeyers, ALAhl, JCincotta, SLZun, LGulliver, AH et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol 2007;22(7):455–62.
[59]Katagiri, HFujikoshi, SSuzuki, TFujita, KSugiyama, NTakahashi, M et al. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry 2013; 13:20.
[60]San, LArranz, BQuerejeta, IBarrio, SDe la Gandara, JPerez, VA naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006;21(8):539–43.
[61]Suzuki, HGen, KA naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia. Neuropsychiatr Dis Treat 2013; 9:1281–7.
[62]Daniel, DGPotkin, SGReeves, KRSwift, RHHarrigan, EPIntramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155(2):128–34.
[63]Lesem, MDZajecka, JMSwift, RHReeves, KRHarrigan, EPIntramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62(1):12–8.
[64]Preval, HKlotz, SGSouthard, RFrancis, ARapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005;27(2):140–4.
[65]Allen, MHFeifel, DLesem, MDZimbroff, DLRoss, RMunzar, P et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(10):1313–21.
[66]Kwentus, JRiesenberg, RAMarandi, MManning, RAAllen, MHFishman, RS et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012;14(1):3140.
[67]Lesem, MDTran-Johnson, TKRiesenberg, RAFeifel, DAllen, MHFishman, R et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011;198(1):51–8.
[68]Patrizi, BNavarro Haro, MVGassol, MEffectiveness of inhaled loxapine (IL) in agitated patients diagnosed with personality disorder (PD) – a first approach. Eur Neuropsychopharmacol 2017; S8545.
[69]Calver, LIsbister, GKHigh dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. Br J Clin Pharmacol 2014;77(5):880–6.
[70]Calver, LPage, CBDownes, MAChan, BKinnear, FWheatley, L et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med 2015;66(3):230–8 e1.
[71]Macht, MMull, ACMcVaney, KECaruso, EHJohnston, JBGaither, JB et al. Comparison of droperidol and haloperidol for use by paramedics: assessment of safety and effectiveness. Prehosp Emerg Care 2014;18(3):375–80.
[72]Jibson, MDPsychopharmacology in the emergency room. J Clin Psychiatry 2007;68(5):796–7.
[73]Rocca, PVillari, VBogetto, FManaging the aggressive and violent patient in the psychiatric emergency. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):586–98.
[74]Bak, Mvan Os, JMarcelis, M[Rapid tranquillisation; review of the literature and recommendations]. Tijdschr Psychiatr 2011;53(10):727–37.
[75]NICE, NICE-guideline: violence and aggression. NICE-Guideline: violence and aggression: short-term management in mental health, health and community settings: updated edition London 2015.
[76]Wilson, MPMinassian, ABahramzi, MCampillo, AVilke, GMDespite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department. J Emerg Med 2014;46(6):808–13.
[77]Hockenhull, JCWhittington, RLeitner, MBarr, WMcGuire, JCherry, MG et al. A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8. Health Technol Assess (Rockv) 2012;16(3):1152.
[78]Pratt, JPChandler-Oats, JNelstrop, LBranford, DPereira, SEstablishing gold standard approaches to rapid tranquillisation: A review and discussion of the evidence on the safety and efficacy of medications currently used. J Psychiatr Intensive Care 4(1&2)2008; 4357.

Keywords

Related content

Powered by UNSILO
Type Description Title
PDF
Supplementary Figures S1-S3

Bak et al. Supplementary Material
Bak et al. Supplementary Material

 PDF (790 KB)
790 KB
WORD
Supplementary Tables S1-S3

Bak et al. Supplementary Material
Bak et al. Supplementary Material

 Word (24 KB)
24 KB

The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis

  • Maarten Bak (a1) (a2), Irene Weltens (a1) (a2), Chris Bervoets (a3), Jürgen De Fruyt (a4), Jerzy Samochowiec (a5), Andrea Fiorillo (a6), Gaia Sampogna (a7), Przemyslaw Bienkowski (a8), W. Ulrich Preuss (a9), Blazej Misiak (a10), Dorota Frydecka (a11), Agnieszka Samochowiec (a12), Emma Bak (a13), Marjan Drukker (a1) and Geert Dom (a14)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis

  • Maarten Bak (a1) (a2), Irene Weltens (a1) (a2), Chris Bervoets (a3), Jürgen De Fruyt (a4), Jerzy Samochowiec (a5), Andrea Fiorillo (a6), Gaia Sampogna (a7), Przemyslaw Bienkowski (a8), W. Ulrich Preuss (a9), Blazej Misiak (a10), Dorota Frydecka (a11), Agnieszka Samochowiec (a12), Emma Bak (a13), Marjan Drukker (a1) and Geert Dom (a14)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *